Let me tell you, folks, we’ve got something incredible here. It’s called Vagal Neurostimulation, VNS for short, and it’s changing the game for people suffering from epilepsy and, listen to this, major depression that just doesn’t respond to other treatments. We’re talking about a real solution for those who’ve tried everything. This isn’t just any treatment; it’s a breakthrough with both neuropsychiatric functions and systemic anti-inflammatory activity. Tremendous, right?

We took a group, a fantastic group of six patients who were really struggling with refractory depression. These are people who hadn’t found relief anywhere else. We used the best scales out there – the Montgomery-Asberg Depression Rating and the Hamilton Anxiety Rating Scale – to really see how they were doing. And guess what? After we started VNS, the results were unbelievable. The average depression severity score dropped by 59.9%. Can you believe that? Nearly 60%! And the response rate was 87%. Plus, their anxiety? Down significantly.

But wait, there’s more. We looked at their blood, at forty soluble molecules, before and after VNS. The changes were huge. Levels of IL-7, CXCL8, CCL2, and a bunch of others were significantly lower. And bFGF levels went up. The numbers don’t lie, folks (p values from 0.004 to 0.02). This is the first study of its kind to show the long-term efficacy of VNS and its impact on inflammatory biomarkers. We’re talking about a potential revolution in treating refractory depression. VNS might just be the key to modulating inflammation, improving blood-brain barrier integrity, and reducing inflammatory cell recruitment. This is big, folks. We’re opening doors to new treatment pathways. It’s going to be huge.